Literature DB >> 10718018

The Medicare prescription drug benefit: how will the game be played?

H A Huskamp, M B Rosenthal, R G Frank, J P Newhouse.   

Abstract

Most recent proposals to add a prescription drug benefit to the Medicare program suggest using pharmacy benefit managers (PBMs) to control costs and promote quality. However, the proposals give little detail on the institutional arrangements that would govern PBM operations and drug procurement. The recent Congressional Budget Office cost estimate of the Clinton administration's proposal reflects this lack of detail on how PBMs would function. We sketch an approach for structuring PBM operations that focuses on competition among PBMs, manufacturers, and distributors; incentive pricing; and risk sharing with PBMs.

Mesh:

Year:  2000        PMID: 10718018     DOI: 10.1377/hlthaff.19.2.8

Source DB:  PubMed          Journal:  Health Aff (Millwood)        ISSN: 0278-2715            Impact factor:   6.301


  9 in total

1.  Pharmaceutical cost containment with reference-based pricing: time for refinements.

Authors:  Sebastian Schneeweiss; Malcolm Maclure; Colin Dormuth; Jerry Avorn
Journal:  CMAJ       Date:  2002-11-26       Impact factor: 8.262

2.  Exploring the demand for a voluntary Medicare prescription drug benefit.

Authors:  Richard R Cline; David A Mott
Journal:  AAPS PharmSci       Date:  2003

3.  Fixing flaws in Medicare drug coverage that prompt insurers to avoid low-income patients.

Authors:  John Hsu; Vicki Fung; Jie Huang; Mary Price; Richard Brand; Rita Hui; Bruce Fireman; William H Dow; John Bertko; Joseph P Newhouse
Journal:  Health Aff (Millwood)       Date:  2010-10-28       Impact factor: 6.301

4.  The impact of reference pricing of nonsteroidal anti-inflammatory agents on the use and costs of analgesic drugs.

Authors:  Paul V Grootendorst; John K Marshall; Anne M Holbrook; Lisa R Dolovich; Bernie J O'Brien; Adrian R Levy
Journal:  Health Serv Res       Date:  2005-10       Impact factor: 3.402

5.  Reference drug programs: effectiveness and policy implications.

Authors:  Sebastian Schneeweiss
Journal:  Health Policy       Date:  2006-06-13       Impact factor: 2.980

6.  Impact of reference-based pricing for angiotensin-converting enzyme inhibitors on drug utilization.

Authors:  Sebastian Schneeweiss; Stephen B Soumerai; Robert J Glynn; Malcolm Maclure; Colin Dormuth; Alexander M Walker
Journal:  CMAJ       Date:  2002-03-19       Impact factor: 8.262

7.  Distributing $800 billion: an early assessment of Medicare Part D risk adjustment.

Authors:  John Hsu; Jie Huang; Vicki Fung; Mary Price; Richard Brand; Rita Hui; Bruce Fireman; William Dow; John Bertko; Joseph P Newhouse
Journal:  Health Aff (Millwood)       Date:  2009 Jan-Feb       Impact factor: 6.301

8.  Does knowledge of medication prices predict physicians' support for cost effective prescribing policies.

Authors:  Jennifer M Polinski; Malcolm Maclure; Blair Marshall; Alan Cassels; Jessica Agnew-Blais; Amanda R Patrick; Sebastian Schneeweiss
Journal:  Can J Clin Pharmacol       Date:  2008-07-19

9.  Developing Performance Measures for Prescription Drug Management.

Authors:  Anita J Chawla; Marjorie R Hatzmann; Stacey R Long
Journal:  Health Care Financ Rev       Date:  2001
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.